68692-50-2Relevant academic research and scientific papers
PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
-
, (2012/10/07)
A compound of formula (I) or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammato
NOVEL COMPOUNDS
-
, (2012/09/22)
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammat
Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGluR2 receptor
Garbaccio, Robert M.,Brnardic, Edward J.,Fraley, Mark E.,Hartman, George D.,Hutson, Pete H.,O'Brien, Julie A.,Magliaro, Brian C.,Uslaner, Jason M.,Huszar, Sarah L.,Fillgrove, Kerry L.,Small, James H.,Tang, Cuyue,Kuo, Yuhsin,Jacobson, Marlene A.
scheme or table, p. 406 - 410 (2011/02/21)
Novel oxazolobenzimidazoles are described as potent and selective positive allosteric modulators of the metabotropic glutamate receptor 2. The discovery of this class and optimization of its physical and pharmacokinetic properties led to the identificatio
OXAZOLOBENZIMIDAZOLE DERIVATIVES
-
, (2009/12/23)
The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
